Topical non-barrier agents for postoperative adhesion prevention in animal models.
Pelvic adhesion can form as a result of inflammation, endometriosis or surgical trauma. Most surgical procedures performed by obstetrician-gynecologists are associated with pelvic adhesions that may cause subsequent serious sequelae, including small bowel obstruction, infertility, chronic pelvic pain, and difficulty in postoperative treatment, including complexity during subsequent surgical procedures. An increasing number of adhesion reduction agents, in the form of site-specific and broad-coverage barriers and solutions, are becoming available to surgical teams. The most widely studied strategies include placing synthetic barrier agents between the pelvic structures. Most of the adhesions in the barrier-treated patients develop in uncovered areas in the abdomen. This fact suggests that the application of liquid or gel anti-adhesive agents to cover all potential peritoneal lesions, together with the use of barrier agents, may reduce the formation of postoperative adhesions. This article introduces the topical choices available for adhesion prevention mentioned in preliminary clinical applications and animal models. To date there is no substantial evidence that their use reduces the incidence of postoperative adhesions. In combination with good surgical techniques, these non-barrier agents may play an important role in adhesion reduction.
Imai
Atsushi
A
Institute of Endocrine-Related Cancer, Matsunami General Hospital, Kasamatsu Gifu 501-6062, Japan. aimai@matsunami-hsp.or.jp
Suzuki
Noriko
N
D000081:Acetamides; D000975:Antioxidants / Q000627:therapeutic use*; D024042:Collagen Type I / Q000627:therapeutic use; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005936:Glucans / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006722:Honey; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000077607:Icodextrin; D007249:Inflammation / Q000517:prevention & control; D000069349:Linezolid; D008550:Melatonin / Q000627:therapeutic use; D023303:Oxazolidinones; D010149:Postoperative Pain / Q000517:prevention & control; D017699:Pelvic Pain / Q000517:prevention & control; D010388:Pelvis / Q000601:surgery; D010532:Peritoneal Diseases / Q000517:prevention & control*; D010713:Phosphatidylcholines / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D000267:Tissue Adhesions / Q000517:prevention & control*; D016896:Treatment Outcome
D000081:Acetamides; D000975:Antioxidants; D024042:Collagen Type I; D005936:Glucans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D023303:Oxazolidinones; D010713:Phosphatidylcholines; D000077607:Icodextrin; D005337:Fibrin; D000069349:Linezolid; D005947:Glucose; D008550:Melatonin